Caroline Boulliat | Immunology, Oncology. Biosimilar Business Unit Head
Amgen Europe Gmbh

Caroline Boulliat, Immunology, Oncology. Biosimilar Business Unit Head, Amgen Europe Gmbh

Responsible for Launching INFLECTRA, (first 'Mab' biosimilar ) in the EMEA region
Potential Value: 2 Billions.
In charge of commercial / Marketing / Market Access activities

Appearances:



Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:50

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

  • Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
     
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gainsharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines?

Biosimilars Day 1 - Tuesday 31st October 2017 @ 14:50

Successful implementation of biosimilars in the market: a commercial perspective

back to speakers